Estandarización de ensayos inmunoenzimáticos (ELISA) para la cuantificación de anticuerpos IgG inducidos por una vacuna de vesículas de membrana externa de los serogrupos A y W135 de Neisseria meningitidis

invasive meningococcal disease constitutes a worldwide health problem. gram negative bacteria, neisseria meningitidis is the causal agent of this disease. plain or conjugated polysaccharide vaccines are available against four of five serogroups responsible of more than 95% of cases in the world. because serogroup b polysaccharide is non immunogenic, some vaccine candidates, based on outer membrane proteins have been obtained and evaluated in clinical trials. bactericidal activity determination and elisa igg have been used to evaluate immune response generated by antimeningococcal vaccines. the latter has been used, as potency test, to release va-mengoc-bc？ vaccine lots, produced at finlay institute. as a result of the collaboration with norwegian researchers, a vaccine candidate based on outer membrane proteins against serogroups a and w 135 , has been obtained and evaluated in animal models. the current work describes the standardization of an elisa method to be used in the immune response evaluation of the bivalent vaccinal candidate.